Malignant blood disorders
Adult: Initially: 175-300 mg/m2 given in divided doses over 3-7 consecutive days via IV infusion over 30-60 minutes. Maintenance: 25-100 mg/m2 in a single infusion every 3-4 wk.
Chỉ định và Liều dùng
Intravenous
Malignant blood disorders Adult: Initially: 175-300 mg/m2 given in divided doses over 3-7 consecutive days via IV infusion over 30-60 minutes. Maintenance: 25-100 mg/m2 in a single infusion every 3-4 wk.
|
Chống chỉ định
Pregnancy, lactation; CV disease.
|
Thận trọng
Myocardial irradiation and use of radiotherapy. Hepatic or renal impairment. Elderly.
|
Tác dụng không mong muốn
Nausea, vomiting, mucositis, irritant to tissue, sore mouth, bone-marrow suppression, hyperuricaemia. Alopoecia (rare).
Potentially Fatal: Cardiotoxicity (rare), myelosuppression in patients who received mitomycin or a nitrosourea, leucopenia. |
Tương tác
Other cardiotoxic drugs e.g. daunorubicin or cyclophosphamide, live vaccines; decreases effects of digoxin, oral anticoagulants, phenytoin and suxamethonium.
|
Ảnh hưởng đến kết quả xét nghiệm
Elevated bilirubin level.
|
Tác dụng
Description:
Mechanism of Action: Aclarubicin is an anthracycline, a cytotoxic antibiotic, and inhibits RNA synthesis through intercalation. Pharmacokinetics: Distribution: Rapidly distributed into tissues after IV admin. Metabolism: Extensively metabolised. Excretion: Triphasic clearance. Terminal elimination half-life: About 3 hr. Excreted in urine mainly as metabolites. |
Phân loại MIMS
|